… mutations in non-small-cell lung cancer (NSCLC) in 2004 heralded the era of molecular
classification of lung cancer and precision cancer medicine in lung cancer. Citation1 – Citation3 …

… Lung cancer or lung carcinoma is defined as the uncontrolled proliferation of normal lung
cells due to the genetic damage and it has the capacity to invade the neighboring tissues and …

… The current model may have served us well in the bygone era dominated only by cytotoxic
chemotherapies. Clinical trial processes for cancer therapy in general and NSCLC in …

… Non–small-cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide.
Because most patients will have a diagnosis of advanced disease, localized intervention will …

Full article: Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients
with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Skip …

… Gefitinib, the small molecule inhibitor of the epidermal growth factor receptor (EGFR), was
tested in a randomized phase II study in lung cancer patients using two different dose levels, …

… Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death worldwide,
although important advances in target therapy have been developed in the past few years. …

… of lung cancer in those very soldiers who had served in the trenches. At first they thought the
rise in the incidents of lung cancer … correlation between smoking and lung cancer, than was …

… The best anti-proliferative activity for the examined thiazolyl-pyrazolines was observed
against the non-small lung cancer cells (NSCLC). Compounds 10b and 10d displayed …

… This retrospective population-based study included patients with non-small cell lung cancer
(… Pathological diagnosis of lung cancer was defined by the World Health Organization …